Biotech

Startups News

Biotech Startups Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 23.02.2022.

#GoodDayBIO
#geneediting
#BIOCEO22
#genetherapy
#Alzheimers
#RareDisease
#OneHealth

Startups

@IAmBiotech shared
On Feb 17, 2022
Read @DrMichelleBIO's latest in @BarronsOnline “Biotech Is Creating the Jobs of the Future. It’s Time to Give It a Boost.” https://t.co/xIMkWwn2zQ
Open
Biotech Is Creating the Jobs of the Future. It’s Time to Give It a Boost.

Biotech Is Creating the Jobs of the Future. It’s Time to Give It a Boost.

The booming biotech industry in America is clustered around certain areas for a reason, writes Michelle McMurry-Heath.

@IAmBiotech shared
On Feb 17, 2022
#GoodDayBIO: Recap of Day 3 of #BIOCEO22 2ith the outlook on #genetherapy and #geneediting and how start-ups can get funding. https://t.co/vOcJjHK6m5
Open
Good Day BIO: Gene therapy market will soon follow the science

Good Day BIO: Gene therapy market will soon follow the science

We recap Day 3 of the CEO & Investor Conference with the outlook on gene therapy and gene editing, and how start-ups can get funding. (784 words, 3 minutes, 55 seconds)

@FlagshipPioneer shared
On Feb 17, 2022
Watch this short video about our Fellowship, and check out full details on our website: https://t.co/2hj1a4RF6U https://t.co/XZtQhmMjiz
Open
Join Us

Join Us

Key benefits include: Tap into our unique position in the innovation ecosystem Work directly with Flagship’s highly-experienced team members—a group of widely recognized scientists, ...

@BentheFidler shared
On Feb 22, 2022
Lilly puts $700M into genetic medicine institute https://t.co/XZQuN9ICut by @realJacobBell $LLY $PRVL
Open
Lilly puts $700M into genetic medicine institute

Lilly puts $700M into genetic medicine institute

Building on Lilly's acquisition of Prevail Therapeutics, the Boston-based facility will use RNA- and DNA-based technologies to develop new drugs, while also supporting biotech startups in ...

@IAmBiotech shared
On Feb 22, 2022
#GoodDayBIO: What the newly confirmed FDA Commissioner said about #OneHealth, why CMS “ambushed” efforts to combat pediatric #Alzheimers, and the start of #RareDisease Week. https://t.co/TvUyrdAIY2
Open
Good Day BIO: New FDA commissioner puts animals on agenda

Good Day BIO: New FDA commissioner puts animals on agenda

Beginning the short week with what the newly confirmed FDA Commissioner said about One Health, why CMS “ambushed” efforts to combat pediatric Alzheimer’s, and the start of Rare Disease ...

@MassBio shared
On Feb 22, 2022
RT @frequencytx: Our CEO @davidlucchino's path to life science leadership is one of tenacity and perseverance, overcoming childhood dyslexia to become a life sciences entrepreneur. https://t.co/YF1dYiyPL6
Open
Dyslexic To Disruptor: Frequency Therapeutics CEO David Lucchino Is Working To Reverse Hearing Loss

Dyslexic To Disruptor: Frequency Therapeutics CEO David Lucchino Is Working To Reverse Hearing Loss

David Lucchino, Frequency Therapeutics cofounder and CEO, is a life sciences entrepreneur with nearly two decades of executive leadership experience. Lucchino is dyslexic.

@GENbio shared
On Feb 23, 2022
.@LillyPad said today it has launched a $700 Institute for Genetic Medicine in Boston’s Fort Point section as part of its strategy to advance RNA- and other nucleic acid-based therapeutics. Learn more: https://t.co/W75l9FUHz4 https://t.co/zRUVaQAYgr
Open
Lilly Plans $700M Genetic Medicine Institute in Boston

Lilly Plans $700M Genetic Medicine Institute in Boston

Eli Lilly said today it has launched a $700 Institute for Genetic Medicine in Boston’s Fort Point section as part of its strategy to advance RNA- and other nucleic acid-based therapeutics.

@IAmBiotech shared
On Feb 22, 2022
Important article by Thomas Mathers, allievex President and CEO, on CMS’s unprecedented decision to restrict coverage for drugs used to treat patients suffering from Alzheimer’s. https://t.co/56mXzOg9Ji
Open
Mathers: CMS decision puts future disease cures in crosshairs

Mathers: CMS decision puts future disease cures in crosshairs

If the FDA ultimately approves our drug, it could save the lives of thousands of children with Sanfilippo Syndrome worldwide.